Real‐world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: Results of a single centre retrospective study (BroSwitch)
Abstract Background Biologicals are a widely used treatment for psoriasis (PsO), however, biologicals are expensive and while continuous use is warranted, sometimes need switching. In January 2021, dermatologists of Bravis Hospital and dermaTeam clinic actively switched 91 patients, who received Ixe...
Saved in:
Main Authors: | Jolijn C. Bethlem (Author), Jenny A. H. M. Janssens (Author), Milan Tjioe (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023) -
Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
by: Annunziata Raimondo, MD, et al.
Published: (2021) -
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
by: Lisa Schaeffer, et al.
Published: (2024) -
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
by: Mark Lebwohl, et al.
Published: (2024) -
Switching Off Key Signaling Survival Molecules to Switch On the Resolution of Inflammation
by: Denise Alves Perez, et al.
Published: (2014)